![PARI Pharma's eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) PARI Pharma's eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed's ARIKAYCE® (amikacin liposome inhalation suspension)](https://mma.prnewswire.com/media/753414/Lamira_Nebulizer_System.jpg?p=facebook)
PARI Pharma's eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed's ARIKAYCE® (amikacin liposome inhalation suspension)
![The Pari eFlow (called APIXNEB when used with the AKITA) open-mesh,... | Download Scientific Diagram The Pari eFlow (called APIXNEB when used with the AKITA) open-mesh,... | Download Scientific Diagram](https://www.researchgate.net/publication/51671779/figure/fig4/AS:312817015115779@1451592796655/The-Pari-eFlow-called-APIXNEB-when-used-with-the-AKITA-open-mesh-vibrating-mesh.png)
The Pari eFlow (called APIXNEB when used with the AKITA) open-mesh,... | Download Scientific Diagram
![Magnair™ an eFlow® Closed System Nebulizer together with Sunovion's Lonhala™ is the first eFlow technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD) Magnair™ an eFlow® Closed System Nebulizer together with Sunovion's Lonhala™ is the first eFlow technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)](https://mma.prnewswire.com/media/616445/PARI_Pharma_Lonhala_Magnair_Inhalation_Solution.jpg?p=facebook)